GoldenGolden
Advanced Search
SutroVax

SutroVax

An independent vaccine platform in California that focuses on delivering best-in-class conjugate vaccines and complex antigen-based vaccines to prevent deadly infectious diseases.

SutroVax is an independent vaccine platform in California that focuses on delivering best-in-class conjugate vaccines and complex antigen-based vaccines to prevent deadly infectious diseases. Founded 2013 in Foster City, California, United States by Ash Khanna, Grant E. Pickering and Jeff Fairman, it is a developer of conjugate and novel complex antigen-based vaccines intended to prevent serious infectious diseases. The company's cell-free protein synthesis platform permits site-specific conjugation, enabling the creation of conjugate vaccines with the potential to deliver heightened immunity and broader protection.

Timeline

March 2020
SutroVax raises a $110,000,000 series D round from Janus Henderson Investors and RA Capital.
June 2018
SutroVax raises a $85,000,000 series C round from Abingworth, CTI Life Sciences Fund, Foresite Capital, Frazier Healthcare Partners, Longitude Capital, Medicxi Ventures, Pivotal bioVenture Partners, Roche Venture Fund and TPG Growth.
March 21, 2017
SutroVax raises a $60,000,000 series B round from Frazier Healthcare Partners.
March 2017
SutroVax raises a $60,000,000 series B round from Abingworth, CTI Life Sciences Fund, Frazier Healthcare Partners, Longitude Capital, Pivotal bioVenture Partners and Roche Venture Fund.
2013
Founded

Funding rounds

People

Name
Role
LinkedIn

Ash Khanna

Founded

Jeff Fairman

Founded

Grant E. Pickering

Founded

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.